What is the MeMed BV® test studying for respiratory infections?

The MeMed BV® test is being studied to see if it helps doctors quickly tell if a respiratory infection is caused by bacteria or viruses. This trial aims to find out if using this test early in emergency care improves management and reduces unnecessary treatments or hospital stays. The University of Texas Health Science Center is leading this research to improve care quality and resource use.

Who may be eligible for this respiratory infection clinical trial?

Adults aged 18 or older with an acute respiratory illness lasting 7 days or less and a recent fever may be eligible. The study includes those with suspected bacterial or viral infections who have not recently taken antibiotics or steroids and are not pregnant. Both men and women can participate. Please review eligibility criteria for more details.

Is there any cost to participate in this respiratory infection clinical trial?

Study-related care, including the diagnostic test and all trial visits, is provided at no cost. However, personal travel expenses to attend study visits may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel expenses.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID06070688

Evaluating an Early Diagnostic Blood Test to Differentiate Bacterial and Viral Respiratory Infections in Adults at the Emergency Department

Led by The University of Texas Health Science Center, Houston · Updated on 2026-01-23

100

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are investigating whether adding a diagnostic test that can distinguish whether an acute respiratory illness is caused by bacteria or viruses early in the evaluation can improve patient management and reduce healthcare resource use. The study focuses on adults presenting to the Emergency Department ED with undiagnosed respiratory infections who meet SIRS criteria and require immediate blood tests and treatment. The goal is to see if this test affects decisions about further diagnostic work, antimicrobial use, hospital stay length, and related costs. Participants are randomly assigned to one of two groups. The experimental group receives the usual care plus results from the MeMed BVae biomarker test, which analyzes a blood sample to provide a score that may help guide treatment. The control group receives standard care without the test results. Both groups are managed by clinicians following standard practice protocols. The study aims to compare outcomes such as additional testing, use of antibiotics, hospital admissions, and length of stay between these groups. During the study, participants will be monitored from admission to the ED through about 28 days of follow-up. Researchers will track costs related to diagnostic tests, consultations, antimicrobial treatments, hospital stays, and emergency department visits. They will also assess hospital length of stay up to six months post-admission, the number of patients returning to the ED within 72 hours, and appropriate antibiotic use based on infection type. Safety and patient management quality will be evaluated by reviewing these clinical and resource measures.

CONDITIONS

Brief Title

An Adjunct Test Distinguishing Bacterial From Viral Etiology Improves Resource Utilization and Efficiency in the ED.

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Current disease duration is 7 days or less
Temperature of 37.8°C (100°F) or higher, or tactile fever, noted at least once within the last 7 days
Clinical suspicion of bacterial or viral respiratory tract infection (RTI)
Written informed consent obtained from patient or legal guardian
Clinical suspicion of bacterial or viral sepsis based on 2 or more SIRS criteria or RTI with fever as above

You will not qualify if you...

Systemic antibiotics taken up to 48 hours prior to presentation
Outpatient steroids taken within 48 hours prior to presentation
Suspicion or confirmed diagnosis of infectious gastroenteritis or colitis
Inflammatory diseases such as IBD, SLE, RA, or vasculitis
Congenital immune deficiency
Proven or suspected infection with Mycobacterial, parasitic, or fungal pathogens
HIV, Hepatitis B, or Hepatitis C infection
Major trauma or burns within the last 7 days
Major surgery within the last 7 days
Pregnancy, self-reported or medically confirmed
Active malignancy diagnosed within the last six months or not in remission
Current treatment with immune-suppressive or immune-modulating therapies within the past 10 days
Hemodynamically unstable requiring life-saving interventions
Patients transferred from another facility with a known respiratory diagnosis
Considered unsuitable for the study by the study team

Research Team

David Robinson, MD,MS,MMM

Neomi Sepulveda

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Evaluating an Early Diagnostic Blood Test to Differentiate Bacterial and Viral Respiratory Infections in Adults at the Emergency Department

On this page

AI-Summary

What this Trial Is About

Brief Title

Who Can Participate

Eligibility Criteria

Research Team

Not the Right Trial for You?

On this page

Who Can Participate

Eligibility Criteria